Category - Developments

Cellectar Biosciences (NASDAQ:CLRB) has announced the results of the first phase of a NCI-funded Small Business Innovation Research (SBIR) Phase 1 contract for a study of CLR 125, a radiotherapeutic isotope, which may...

Anavex Life Sciences (NASDAQ:AVXL) has received FDA orphan drug designation for ANAVEX 2-73 for the treatment of infantile spasms. ANAVEX 2-73 already has orphan drug designation for the treatment of Rett syndrome. An...

Profound Medical (TSX-V:PRN) and Royal Philips have jointly sold a TULSA-PRO system to University Hospital of Cologne, the first sale in Germany, following CE Mark approval in April 2016. TULSA-PRO is an innovative...

OrbiMed will join a $10-million financing round by closely-held NovellusDx led by IntraCure, a public life science holding company, and Pontifax, a leading Israeli life sciences VC, raising the size of the round to $12...

Oramed Pharmaceuticals (NASDAQ:ORMP) has received a $6.5-million milestone payment from Hefei Tianhui Incubator of Technologies (HTIT) under a December 2015 license and investment agreement. The payment follows Oramed’s...

The first 10 patients received treatment last week with Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine, following FDA approval on May 26. ProbuphineProbuphine was developed using Titan’s long...

Avivagen (TSX-V:VIV) has provided results of four new trials of OxC-beta livestock as a feed additive for swine in the Philippines and Vietnam, and broiler poultry in the Philippines and Spain. In a new trial with the...

Dipexium Pharmaceuticals (NASDAQ:DPRX) and research collaborator, R. M. Alden Research Laboratory, presented data from two new Locilex microbiology studies at the American Society for Microbiology’s Microbe conference...

NBC News has become the latest media outlet to feature Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant for people addicted to heroin and prescription painkillers. As an implantable version of oral buprenorphine...

The peer-reviewed medical journal, Clinical Pharmacology in Drug Development, has published the combined results of two Phase 1 clinical trials by Juniper Pharmaceuticals (NASDAQ:JNP) that demonstrated the safety and...